Stocks in the healthcare sector were flat amid a broader stock market rise.
Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara.
Elevance Health fell 9% although the health insurer beat earnings estimates and boosted its full-year outlook for the second time in months.
Boehringer Ingelheim said its Jardiance diabetes drug helped it increase sales in the first half, as the German drugmaker gears up to file for U.S. approval of a new obesity medicine.
Write to Paulo Trevisani at paulo.trevisani@wsj.com
(END) Dow Jones Newswires
July 15, 2026 17:59 ET (21:59 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments